Inside Oscar Health Q2 2024 Earnings: Record Growth and Profitability

When Oscar Health dropped its Q2 2024 earnings, it wasn’t just another quarterly check-in. It was a statement: the company is scaling faster, executing smarter, and finally showing the kind of profitability metrics that investors have been waiting for.

With revenue jumping 46% year-over-year to $2.2 billion and membership hitting an all-time high of 1.6 million members, this was the quarter that proved Oscar’s tech-driven model can compete in a highly regulated, competitive health insurance market.

Full details are also available in Oscar Health’s official Q2 2024 press release.

---

---

If you’ve followed Oscar Health over the years, you’re likely familiar with the company’s reputation as a disruptor that has often been seen as promising more than it could deliver. But Q2 2024 shows a different story — one of operational discipline, sustainable growth, and confidence in its long-term roadmap.

Let’s dig into why this quarter mattered so much, not just for Oscar Health, but also for investors watching OSCR stock closely.

---

Key Takeaways — Oscar Health Q2 2024 Earnings

• Revenue surged 46% YoY to $2.2B, driven by membership expansion and retention.
• Membership hit 1.6M, up 63% YoY, boosted by Special Enrollment Period (SEP) additions from Medicaid redeterminations.
• Profitability inflection point: Adjusted EBITDA reached $104.1M, net income hit $56M ($0.20/share).
• Guidance raised: Full-year revenue outlook lifted to $9–9.1B, with adjusted EBITDA forecast now $160M–$210M.
• MLR steady at 79% in Q2, with short-term SEP headwinds expected to flip into 2025 tailwinds.
• SG&A efficiency gains: Expense ratio fell to 19.6%, down 260 bps YoY.
• Capital position strong: $4.1B in cash and investments, with $655M in excess capital.
• 2027 roadmap intact: 20% revenue CAGR, 5% operating margin targets remain the long-term guide.

---

---

Why This Quarter Mattered for Oscar Health

The second quarter of 2024 was Oscar’s best yet, by multiple measures. Revenue surged, profitability improved, and the company raised its full-year guidance. In fact, CEO Mark Bertolini called the first half of 2024 “the best six months in Oscar’s history.”

Here are the big reasons Q2 was a turning point:

• Revenue growth was massive. $2.2 billion in Q2 revenue, up 46% YoY, shows Oscar’s scaling power.
• Profitability is improving. Adjusted EBITDA came in at $104.1 million, nearly $70 million higher than Q2 2023.
• Membership surged. 1.6 million members represents 63% year-over-year growth.
• Guidance is up. Full-year revenue guidance was raised by $700 million, now at $9–9.1 billion.

The message was clear: Oscar isn’t just surviving in the individual health insurance market — it’s thriving.

“The first half of 2024 is the best six months in Oscar’s history. Our outperformance in Q2 increases our confidence in achieving long-term goals.” — Mark Bertolini, CEO

For retail investors, these results are significant because they indicate that Oscar Health is transitioning beyond its reputation as a cash-burning startup and toward becoming a profitable, scaled player in the health insurance industry.

---

Revenue Growth and Membership Surge

Oscar Health Revenue Q2 2024: $2.2 Billion

Revenue growth is the first headline. At $2.2 billion in Q2, Oscar delivered a massive 46% year-over-year increase. This wasn’t just about raising prices — it was about sheer volume. Membership expansion and retention both contributed meaningfully to the top line.

Here’s a quick breakdown:

Metric	Q2 2024	YoY Change	Driver
Total Revenue	$2.2B	+46%	Membership growth + rate increases
Membership	1.6M	+63%	Retention, expansion, SEP adds
Adjusted EBITDA	$104.1M	+$69M	Improved MLR + scale efficiencies
Medical Loss Ratio (MLR)	79%	-90 bps	Favorable prior period development

What stands out is how membership growth and favorable utilization trends worked together. Revenue isn’t just inflating due to subsidies or temporary boosts — Oscar is truly winning share in its core markets.

Membership Growth: 1.6 Million and Rising

Oscar ended Q2 with 1.6 million members, a whopping 63% increase year-over-year. This growth came from three major sources:

1. Retention Strength – Oscar kept more members from prior years, showing satisfaction with its plans.
2. Expansion Markets – The company grew in ~80% of states it operates in, expanding its ACA footprint.
3. Special Enrollment Period (SEP) Additions – Medicaid redeterminations pushed individuals into ACA marketplaces, and Oscar captured a meaningful share.

The SEP growth story is particularly interesting. These members create a short-term headwind for the medical loss ratio (MLR) because they join mid-year, which skews the risk adjustment. However, management emphasized that these same members can become a tailwind in 2025 if retained — and Oscar has historically performed well with SEP retention.

Medicaid Redeterminations: A Temporary Boost

As states reassessed Medicaid eligibility, many individuals lost coverage but turned to the ACA marketplace. Oscar was well-positioned to capture these members thanks to its affordable, tech-driven plans and strong broker relationships. CEO Bertolini called this trend “a solid foundation for 2025,” since these new members will renew under traditional enrollment cycles.

In other words, while 2024’s SEP surge temporarily increases costs, the longer-term picture is healthier: younger, often healthier members entering Oscar’s pool and driving down per-member costs.

---

Q2 Growth in Context

• Oscar’s revenue jumped 46% YoY to $2.2B.
• Membership hit 1.6M, growing 63% YoY.
• Medicaid redeterminations fueled SEP growth — a short-term cost headwind, long-term retention tailwind.
• The first half of 2024 set new company records for both revenue and profitability.

---

Profitability and Adjusted EBITDA Outlook

Revenue growth grabs the headlines, but for investors, profitability is what moves stock valuations. Historically, Oscar Health has been viewed as a company that could grow top-line revenue but struggled to turn that growth into consistent earnings. Q2 2024 signaled that this perception may finally be shifting.

Oscar’s adjusted EBITDA in Q2 came in at $104.1 million, nearly $69 million higher than the same quarter last year. For the first half of 2024, adjusted EBITDA totaled $323 million, a staggering $237 million year-over-year improvement. Put simply, this is the most profitable six-month stretch in the company’s history.

CFO Scott Blackley summed it up bluntly:

“We’ve delivered the best six months in Oscar’s history. Our strong outperformance demonstrates that we can achieve growth and improve profitability.”

For a company that has spent years in the red, this is a major inflection point.

---

Adjusted EBITDA Guidance Raised

Management didn’t just report strong profitability — they raised the bar for the rest of 2024. Oscar now expects:

• Adjusted EBITDA: $160M–$210M (previously lower range)
• Total Revenue: $9B–$9.1B (raised by $700M)

As reported by Business Wire.

---

Medical Loss Ratio (MLR): 79% in Q2 2024

One of the key profitability drivers was Oscar’s medical loss ratio (MLR). In Q2, MLR came in at 79%, down 90 basis points year-over-year.

For those new to insurance terms:

• MLR measures the percentage of premiums spent on medical claims.
• A lower MLR means the company keeps more revenue after paying for care.
• Regulators require a minimum MLR (usually ~80% for individual markets), so insurers walk a fine line between efficiency and compliance.

Oscar’s improvement was largely driven by favorable prior period development (roughly $36M in Q2). In plain English, claims came in lower than expected for the previous periods, which gave Oscar some breathing room in terms of profitability.

Looking forward, the company guided full-year MLR to 80.5%–81.5%. The increase compared to Q2 reflects the short-term headwinds faced by SEP members, who typically join later in the year, creating timing mismatches in risk adjustment.

---

SEP Headwinds vs. 2025 Tailwinds

A recurring theme in the earnings call was the dynamics of Special Enrollment Period (SEP) membership.

Here’s how it plays out:

• Short-term (2024): SEP members join mid-year, which creates MLR headwinds. Risk adjustment mechanisms don’t fully capture their risk profile until the following year, leading to artificially higher costs in 2024.
• Long-term (2025+): If retained, these SEP members become just like open enrollment members — often younger, healthier, and less costly.

Mark Bertolini explained this dynamic clearly during Q&A:

“SEP growth comes with an in-year MLR headwind due to partial year risk adjustment dynamics. But we expect these members to be a tailwind in 2025 as we retain them.”

For investors, this means don’t panic about 2024’s MLR guide. The economics of these new members improve meaningfully in the following year.

---

SG&A Expense Ratio: Efficiency Gains

Another important driver of profitability was administrative efficiency. Oscar’s SG&A expense ratio improved 260 basis points YoY to 19.6% in Q2.

That’s a big deal for two reasons:

1. Fixed cost leverage — As membership grows, Oscar spreads its fixed costs (tech platform, operations, corporate staff) across a larger base.
2. Variable cost efficiencies — The company has found ways to reduce per-member operating expenses, particularly in distribution and engagement.

For the full year, Oscar now expects SG&A to be between 19.75% and 20.25%. Management highlighted that these improvements show the scalability of their tech-driven model — every new member strengthens cost efficiency.

---

Net Income: A True Milestone

Perhaps the most symbolic number for investors was net income. Oscar reported $56 million in net income in Q2, or $0.20 per diluted share.

This marks a huge swing from prior years of net losses and helps solidify Oscar’s transition into a company that can scale profitably. First-half net income totaled $234 million, improving nearly $289 million YoY.

Net income is the number Wall Street pays the most attention to. While adjusted EBITDA is useful for understanding operations, positive net income signals that the business model is finally working on GAAP terms.

---

Profitability Snapshot

• Adjusted EBITDA Q2 2024: $104.1M (+$69M YoY)
• First-half EBITDA: $323M (+$237M YoY)
• Net Income Q2 2024: $56M ($0.20/share)
• MLR: 79% in Q2, full-year guide 80.5%–81.5% (temporary SEP headwind)
• SG&A Ratio: 19.6%, improved 260 bps YoY
• Full-year adjusted EBITDA forecast raised to $160M–$210M

---

Q1 2024 Expectations vs. Q2 2024 Delivery

One of the best ways to judge management credibility is to look back at what was promised last quarter and see if it materialized this quarter. Oscar Health’s Q1 2024 earnings call set a strong tone, with bold guidance around membership, profitability, and strategic focus. Here’s how those commitments stacked up in Q2 2024 results.

---

Profitability: From First Net Income to Sustained Gains

• Q1 promise: Management highlighted the company’s first-ever quarterly net income ($178M) and pledged that 2024 would mark total company adjusted EBITDA profitability.
• Q2 delivery: Oscar followed through, reporting another profitable quarter with $56M net income and $104M adjusted EBITDA. First-half EBITDA hit $323M, giving confidence that full-year profitability is on track.

Delivered: Profitability wasn’t a one-off in Q1 — it’s proving sustainable.

---

Membership Growth and Retention

• Q1 promise: Membership grew 42% YoY to 1.4M, and management flagged SEP additions as a major driver to watch. Retention was at record highs, and culturally tailored programs (like HolaOscar) were highlighted as retention levers.
• Q2 delivery: Membership hit 1.6M (+63% YoY), with SEP growth continuing as Medicaid redeterminations played out. Management again stressed SEP retention as the real long-term win, noting younger, healthier profiles among these members.

Delivered: Membership growth accelerated, confirming Q1 expectations. Retention impact from SEP members will be clearer in 2025.

---

Medical Loss Ratio (MLR) Discipline

• Q1 promise: Q1 MLR improved to 74.2% — much lower than full-year guidance of ~80–81%. Management warned that SEP timing would push MLR higher later in the year.
• Q2 delivery: As expected, MLR rose to 79%, with full-year guidance of 80.5%–81.5%. Management tied the increase directly to SEP timing — exactly the dynamic flagged in Q1.

Delivered: The rise in MLR wasn’t a miss — it matched what management telegraphed.

---

SG&A Efficiency

• Q1 promise: SG&A ratio fell to 18.4%, driven by cost leverage and efficiency. Management suggested further improvements ahead.
• Q2 delivery: SG&A came in at 19.6%, up slightly versus Q1 but still down 260 bps YoY. Full-year guidance was set at 19.75%–20.25%, better than initial expectations.

Mixed but Positive: Q2 SG&A ticked up sequentially but remains on track with annual improvement goals.

---

Strategic Focus: ACA, ICRA, and +Oscar

• Q1 promise: Oscar announced its exit from Medicare Advantage and Cigna+Oscar small group, positioning ICRA as the next big growth engine. Investor Day was teased as the stage for long-term strategy.
• Q2 delivery: Investor Day delivered: Oscar set 2027 targets of 20% CAGR revenue and 5% operating margin, with ICRA highlighted as a key lever. Q2 results reinforced momentum in ACA and early traction in ICRA markets like Indiana and Texas. +Oscar campaigns showed measurable success, including an 18% YoY boost in wellness visits.

Delivered: Strategic clarity was sharpened, with concrete long-term goals now guiding investors.

---

Q1 2024 vs. Q2 2024

• Profitability: Sustained, not just a Q1 milestone.
• Membership: Accelerated growth, SEP retention still key for 2025.
• MLR: Rose exactly as forecast due to SEP timing.
• SG&A: Sequential tick-up, but still YoY improvement.
• Strategy: Exit from distractions, doubling down on ACA, ICRA, and +Oscar.

Oscar Health did what it said it would in Q1 — and then some. For investors, that’s the kind of execution that builds credibility quarter by quarter.

---

Strategic Growth Drivers Beyond Q2 2024

Q2 wasn’t just about reporting numbers. Oscar’s leadership used the call to highlight the bigger picture: the strategy that will power the company’s growth into 2025 and beyond. For retail investors, this is where things get especially interesting. Oscar isn’t positioning itself as a run-of-the-mill insurer. It’s building a hybrid identity — part insurer, part tech platform, and part policy innovator — designed to capture growth from multiple angles.

Let’s break down the three big strategic levers: ACA expansion, ICRA adoption, and the +Oscar technology engine.

---

ACA Marketplace Expansion

The Affordable Care Act (ACA) marketplace remains the foundation for Oscar. It’s also one of the fastest-growing markets in U.S. health insurance. Nearly 22 million Americans are enrolled in ACA plans, and Oscar believes the market will continue to expand as more consumers move away from employer-sponsored coverage.

Oscar’s Q2 numbers prove it is capturing this opportunity. Membership rose 63% year-over-year, and the company reported growth in 80% of its states. Retention rates were also strong, which suggests Oscar’s focus on personalized, affordable plans is resonating.

CEO Mark Bertolini emphasized how Oscar’s ACA positioning is about more than pricing:

“We drove more individuals to affordable, culturally competent plans based on our deep understanding of the ACA consumer and our ability to personalize engagement through our technology.”

That last part — personalization through tech — is what differentiates Oscar. Unlike traditional insurers, Oscar isn’t just offering plans. It’s offering a consumer experience, with digital tools that guide members toward lower-cost, higher-quality care.

This is already paying off. For example, Oscar launched campaigns that encouraged members to use Virtual Urgent Care instead of emergency rooms. That single initiative created nearly $18 million in value for Oscar Insurance this year, by lowering costs for both members and the company.

The lesson for investors: Oscar isn’t just scaling membership. It’s also proving it can bend the cost curve through tech-driven engagement, which is crucial for long-term profitability.

---

The Rise of ICRA Health Plans

One of the most intriguing growth stories for Oscar is its push into Individual Coverage Health Reimbursement Arrangements (ICRAs).

Here’s the quick definition: ICRA allows small and mid-sized businesses to give employees a fixed contribution toward health coverage, and then employees choose an ACA marketplace plan. Instead of offering one-size-fits-all group insurance, employers hand over flexibility and choice to their workers.

Oscar sees ICRA as a massive tailwind for several reasons:

1. Affordability pressure: Small and mid-sized businesses are struggling to offer traditional health benefits. ICRA offers a lower-cost, customizable option.
2. Policy momentum: States like Indiana and Texas are passing laws to facilitate ICRA adoption, and more states are likely to follow suit.
3. Employer demand: The model addresses a key pain point for employers who want to offer benefits but can’t afford traditional legacy group plans.

Mark Bertolini was clear about Oscar’s bullish stance:

“The ICRA value proposition is resonating in the market and at state policy levels. We expect other states will follow suit. State momentum keeps us bullish on ICRA as a key solution to give consumers more choice and employers a more sustainable cost structure.”

From an investor’s perspective, this is important. The ICRA market is still in its early stages, but Oscar is positioning itself as a first mover. If adoption accelerates, Oscar could capture a significant share of new lives moving into the ACA system.

---

+Oscar Platform and Tech Advantage

Perhaps the least understood but most powerful lever in Oscar’s strategy is +Oscar, the company’s platform business. Think of it as the B2B arm of Oscar Health. While Oscar Insurance sells ACA and ICRA plans directly to consumers, +Oscar sells the underlying technology and engagement tools to providers, health plans, and other partners.

Why does this matter? Because +Oscar expands revenue opportunities beyond insurance premiums. It allows Oscar to monetize its technology stack, which includes:

• AI-driven engagement models that track member needs in real-time.
• Digital health campaigns that encourage preventive care, like wellness visits.
• Operational efficiency tools that reduce costs for providers and partners.

For example, +Oscar engagement campaigns drove an 18% YoY increase in annual wellness visits among individuals with chronic conditions. That’s not only a revenue driver for providers but also reduces long-term costs by catching health issues earlier.

In short, +Oscar proves that Oscar’s tech isn’t just window dressing. It’s a genuine moat that creates better outcomes for members, providers, and the company itself. For investors, this is a signal that Oscar can eventually diversify revenue streams in a way most insurers cannot.

---

Growth Drivers

• ACA Expansion: Oscar grew in 80% of states, winning share with personalized, affordable plans.
• ICRA Opportunity: States are opening doors to ICRA adoption, positioning Oscar as a first mover.
• +Oscar Platform: Tech-driven engagement campaigns lower costs and create new B2B revenue opportunities.
• Strategic growth is not just top-line expansion — it’s about building a scalable, tech-enabled model.

---

Risks and Policy Factors to Watch

Oscar Health’s Q2 2024 earnings painted a strong picture of growth and profitability. However, no matter how favorable the numbers appear, investors recognize that healthcare stocks inherently carry external risks — ranging from regulatory changes to subsidies to unpredictable enrollment dynamics. For Oscar, three areas stand out: the ACA subsidy debate, risk adjustment mechanics, and Special Enrollment Period (SEP) economics.

Let’s unpack each.

---

The ACA Subsidy Question

Perhaps the biggest macro risk Oscar faces isn’t about its own operations at all — it’s about politics. Enhanced ACA subsidies, introduced under the American Rescue Plan and extended through the Inflation Reduction Act, are set to expire in 2025 unless renewed.

These subsidies are critical because they:

• Lower premiums for millions of ACA enrollees.
• Expand access to coverage to reduce the uninsured rate.
• Help insurers like Oscar attract a broader, healthier risk pool.

Oscar’s management addressed the issue directly on the earnings call. CEO Mark Bertolini made the case that subsidies are not only good policy but also politically sustainable:

“The continuation of enhanced subsidies is a critical bipartisan issue. Subsidies have made affordable comprehensive benefits accessible to hardworking Americans. Without them, the uninsured rate is expected to rise significantly.”

For investors, the takeaway is twofold:

1. Oscar has baked its 2027 targets (20% CAGR revenue, 5% operating margin) assuming subsidies expire, so its base case doesn’t rely on them.
2. If subsidies are extended, it’s pure upside for both membership growth and revenue.

In other words, Oscar is not hostage to the political cycle — but subsidy renewal would supercharge its growth.

---

Risk Adjustment Dynamics

Another factor that can swing earnings is risk adjustment, a mechanism used by the Centers for Medicare & Medicaid Services (CMS) to balance out insurer risk pools.

Here’s the quick primer:

• Insurers with riskier, sicker members receive payments.
• Insurers with healthier members pay into the system.
• The goal is to prevent insurers from cherry-picking only healthy enrollees.

In Q2, Oscar reported that risk adjustment was largely consistent with expectations, based on CMS’s final 2023 report and early 2024 Wakely results. That’s good news — no nasty surprises.

However, SEP members complicate this picture. Because they join mid-year, their health status isn’t fully captured in risk adjustment, leading to a short-term cost headwind. CFO Scott Blackley explained:

“SEP members added in the second half of the year carry an in-year MLR headwind due to partial year risk adjustment dynamics. Historically, we’ve had a good track record of retaining SEP members, and their performance in the following year has been similar to open enrollment members.”

Translation: 2024 will see a temporary bump in MLR because risk scores for SEP members aren’t fully counted. But if Oscar retains those members into 2025, risk adjustment will normalize, and profitability improves.

---

SEP Membership Economics

Special Enrollment Periods (SEP) are one of the biggest growth drivers for Oscar this year, largely due to Medicaid redeterminations. As states reassess eligibility, millions are losing Medicaid coverage and entering ACA marketplaces.

For Oscar, SEP growth is a double-edged sword:

• Short-term: SEP members increase MLR because they typically enter late in the year and immediately begin using care, before risk scores have a chance to catch up.
• Long-term: SEP members tend to be younger and healthier than the average ACA enrollee. Oscar expects strong retention into 2025, which will flip SEP members into a profitability tailwind.

Mark Bertolini highlighted this trend:

“The SEP members we’re getting are three to four years younger than the overall population. They tend to be healthier, which is why when we retain them into the second year, they look a lot like open enrollment members.”

So, while SEP growth pressured full-year MLR guidance (80.5%–81.5%), the bigger story is 2025. If Oscar retains a meaningful share of SEP members, its risk pool will actually improve.

---

Election-Year Policy Overhang

Finally, no investor can ignore the election-year backdrop. Healthcare reform remains a contentious topic, and 2024 will likely be no exception.

The good news for Oscar? The conversation has shifted. Rather than “repeal and replace” the ACA, federal and state policymakers are increasingly focused on improving and expanding marketplaces. That’s a positive structural backdrop for Oscar, which relies on ACA growth for its core business.

Still, volatility around subsidy negotiations or state-level policy changes could create short-term noise for OSCR stock. Investors should expect headlines to outweigh the impact of fundamentals on the stock occasionally.

---

Risk Factors in Focus

• Subsidies: Oscar’s long-term plan assumes expiration, but extension would be upside.
• Risk Adjustment: SEP timing creates temporary headwinds, but retention turns this into a 2025 tailwind.
• Election-Year Volatility: Policy risk is real, but sentiment is shifting toward strengthening ACA, not dismantling it.
• Bottom Line: Oscar has built resilience into its guidance, meaning risks are manageable and upside is possible.

---

Capital Strength and Long-Term Targets

When evaluating a health insurer, growth and profitability matter — but balance sheet strength can be the hidden differentiator. Insurers must hold substantial reserves to cover claims, and their ability to self-fund expansion often depends on the amount of capital surplus they have. In Q2 2024, Oscar Health demonstrated not only rapid growth but also the development of a stronger financial foundation.

---

Strong Cash and Investment Position

Oscar ended the quarter with $4.1 billion in cash and investments, including $204 million held at the parent company. That’s a sizable war chest for a company that only a couple of years ago was under pressure to prove it could sustain operations without constant capital raises.

Breaking it down further:

• Insurance subsidiaries reported $1.1 billion in capital and surplus.
• Of that, $655 million represented excess capital, above the regulatory minimums.

For investors, this is crucial. It means Oscar has the financial flexibility to fund growth, absorb volatility in claims, and reduce reliance on quota share agreements with reinsurance partners.

CFO Scott Blackley emphasized this point:

“With positive earnings trajectory, we will generate significant excess capital through 2027. Scale creates fixed cost leverage, gives us the ability to expand into new markets, and funds our business growth organically.”

---

Quota Share: Temporary but Useful

A key part of Oscar’s capital strategy has been its use of quota share reinsurance. Essentially, quota share allows Oscar to cede a portion of premiums and claims to reinsurance partners, which helps it manage capital requirements while growing.

The trade-off: Oscar gives up some revenue upside in exchange for balance sheet protection.

The long-term plan is clear: as Oscar’s capital surplus grows, the company will rely less on quota share. That means it keeps more premiums in-house, further boosting profitability. Management reiterated that quota share is still an “efficient way” to support growth, but the goal is independence.

For investors, that’s a bullish signal. It means Oscar is maturing into a company that can fund its own expansion without leaning heavily on partners.

---

2027 Targets: The Long-Term Roadmap

Perhaps the most important part of Oscar’s strategy is its 2027 roadmap, which was outlined at Investor Day and reiterated on the Q2 call. The targets are ambitious:

• 20% revenue CAGR (compound annual growth rate)
• 5% operating margin
• Continued geographic expansion in ACA markets
• Meaningful share capture in ICRA adoption
• Scaling of +Oscar platform revenue

Let’s put those numbers in context:

Metric	Q2 2024	2027 Target	Commentary
Revenue	$2.2B (quarterly) / $9–9.1B (FY)	~20% CAGR growth	Growth driven by ACA, ICRA, and retention
Operating Margin	Negative historically, breakeven in 2024	5% by 2027	Scale + tech efficiency
Adjusted EBITDA	$323M (first half 2024)	Sustained profitability	Evidence of execution
Membership	1.6M (Q2 2024)	Multi-million growth	ACA expansion + ICRA

Hitting 20% CAGR in revenue while simultaneously delivering a 5% operating margin would transform Oscar into one of the most profitable players in the individual health insurance market. That combination — growth plus profitability — is what long-term investors look for.

To see how this momentum started, revisit our analysis of Oscar Health’s Q1 2024 financial performance — the stepping stone to today’s record-setting Q2.

---

Why Scale Matters in Insurance

Oscar’s growth strategy isn’t just about hitting bigger numbers for the sake of it. Scale in health insurance creates real structural advantages:

• Lower per-member admin costs (SG&A leverage).
• Bargaining power with providers.
• Stronger risk pools that smooth out volatility.
• Ability to invest in tech and spread fixed costs across more members.

Oscar is already seeing these benefits. Its SG&A expense ratio fell 260 basis points YoY in Q2, showing that every new member improves operating efficiency. By 2027, if membership continues to scale through ACA expansion and ICRA adoption, Oscar should be able to sustain margins that rival those of traditional insurers — while still differentiating itself through technology and consumer experience.

---

The Big Picture: Capital + Growth = Flexibility

For retail investors, the combination of capital strength and long-term targets means Oscar has options. With more than $4 billion in cash and investments, and positive net income in Q2, the company isn’t under pressure to raise capital or slow growth. Instead, it can lean into expansion — whether that’s doubling its ACA footprint, pushing deeper into ICRA markets, or expanding its +Oscar partnerships.

And by signaling a clear 5% operating margin goal by 2027, Oscar is telling investors: we’re not just growing for the sake of it. We’re building a durable, profitable model.

---

Capital and Targets

• Cash + Investments: $4.1B, with $655M in excess capital.
• Quota Share: Still useful, but reliance will decline as surplus grows.
• 2027 Roadmap: 20% revenue CAGR, 5% operating margin.
• Scale Advantage: Larger membership base lowers costs and increases bargaining power.
• Oscar now has the capital flexibility to fund growth organically without relying on external funding.

---

What This Means for OSCR Stock

Oscar Health’s Q2 2024 results sent a clear signal to Wall Street: this isn’t the same company that went public with sky-high promises and heavy losses. With record revenue, net income, and adjusted EBITDA, along with raised guidance for the remainder of 2024, the fundamentals now support a more bullish view of OSCR stock.

So what does this mean for retail investors? Let’s break it down.

---

Investor Sentiment After Q2 2024 Beat

For much of its history, investor skepticism has weighed on Oscar’s stock. The narrative was simple: “Great vision, but can they ever make money?”

Q2 2024 fundamentally changes that narrative. For the first time, Oscar has shown:

• Sustained profitability metrics (positive net income, EBITDA).
• Rapid membership scaling (1.6M members, +63% YoY).
• Improving efficiency ratios (SG&A down 260 bps YoY).

This is exactly the kind of execution investors needed to see before assigning a higher multiple to the stock. For growth-oriented healthcare investors, OSCR is starting to look less like a speculative bet and more like a maturing business.

---

Comparing Oscar to the Market

Employer-sponsored plans often overshadow the individual health insurance market, but that’s where Oscar thrives.

Here’s the broader backdrop:

• The ACA marketplace now covers ~22 million Americans.
• Enrollment has steadily grown as subsidies expanded and Medicaid redeterminations shifted lives into ACA coverage.
• Policy momentum has shifted from threats of repeal to opportunities for expansion.

Oscar is capturing an outsized share of this growth. In Q2, the company expanded in 80% of its states, a clear sign of competitive strength. For investors, this means Oscar isn’t just riding the ACA wave — it’s actively outpacing the market.

---

Valuation and Long-Term Potential

Valuation remains the tricky part. OSCR stock trades at a discount to established insurers like UnitedHealth (UNH) or Centene (CNC), partly because Oscar is still in its early stages of profitability. But that also means upside exists if the company continues to execute.

Three factors could drive the re-rating of OSCR stock:

1. Sustained net income in the back half of 2024 and into 2025.
2. ICRA adoption providing a new growth leg beyond ACA.
3. Reduced reliance on quota share, keeping more revenue in-house.

If Oscar achieves its 2027 targets (a 20% CAGR in revenue and a 5% operating margin), the company will look far more like a profitable mid-tier insurer than a scrappy startup. That shift in perception alone could expand valuation multiples.

---

Risks to Watch

Of course, OSCR stock isn’t risk-free. Investors should keep an eye on:

• Subsidy renewal uncertainty (2025 politics).
• SEP retention rates (critical for turning short-term headwinds into long-term tailwinds).
• Competition in ACA markets — while Oscar is winning share now, rivals could ramp up tech investment.
• Execution on ICRA — the opportunity is real, but still early.

Still, Oscar has done a good job of showing that it can plan for the base case (no subsidies) while leaving upside open if policy winds blow its way.

---

---

Key Takeaways for Investors

Oscar Health’s Q2 2024 earnings were more than just a good quarter — they were a proof point. The company is scaling membership, improving profitability, and laying out a clear path to long-term sustainability.

Here’s what matters most for retail investors:

• Oscar is officially profitable. Net income of $56M and adjusted EBITDA of $104M in Q2 prove the model works.
• Membership growth is robust. 1.6M members (+63% YoY) sets up a strong renewal base for 2025.
• SEP dynamics are temporary. 2024’s MLR headwinds flip into tailwinds in 2025 if retention holds.
• Capital strength is solid. $4.1B in cash and $655M in excess capital give Oscar flexibility.
• Long-term roadmap is compelling. 20% revenue CAGR and 5% operating margin by 2027 could make OSCR stock a very different investment story.

At its core, Oscar Health is demonstrating that technology cannot only make health insurance more affordable for consumers but also more profitable for insurers. For investors, that’s the rare combination of growth, execution, and resilience.

---

OSCR at a Glance

• Ticker: OSCR
• Q2 2024 Revenue: $2.2B (+46% YoY)
• Q2 2024 Net Income: $56M ($0.20/share)
• Membership: 1.6M (+63% YoY)
• Cash & Investments: $4.1B, with $655M excess capital
• Guidance Raised: FY revenue $9–9.1B, EBITDA $160–210M
• 2027 Targets: 20% revenue CAGR, 5% operating margin

Oscar Health isn’t just surviving in the ACA marketplace — it’s thriving. For investors, Q2 2024 was the quarter that turned “show me” into “they’ve shown me.”

---

Oscar Health’s Turning Point

Oscar Health’s Q2 2024 earnings weren’t just a quarterly update — they were a milestone. Revenue surged, membership expanded, profitability arrived, and long-term guidance was raised. The company now stands on a solid financial footing, with $4.1B in cash, a growing surplus, and a clear plan to reduce quota share reliance.

Strategically, Oscar is executing on multiple fronts: scaling its ACA footprint, pioneering ICRA adoption, and leveraging its +Oscar technology platform to improve engagement and lower costs. Policy risks, such as ACA subsidies and SEP timing, remain, but Oscar has structured its growth plan to mitigate them. In short, this isn’t the same Oscar Health of the past — it’s a stronger, leaner, more disciplined company with momentum on its side.

For investors, the message is simple: Oscar is no longer just a “potential disruptor.” It’s proving that tech-driven health insurance can scale profitably. By reading this breakdown, you’ve gained a clear view into how Oscar is navigating growth, managing risks, and setting itself up for durable success.

If Q2 2024 was the quarter that made investors take notice, the years ahead may be the ones that reward those who got in early.

Stay tuned for what’s next. Oscar Health has raised its guidance and set the stage for even more growth. When Q3 2024 earnings drop, we’ll break it all down to see if the company can keep up the momentum.

---

Get More Earnings Breakdowns and Investor Insights

This site is built for retail investors who want straightforward, in-depth breakdowns of earnings calls—without the jargon. Whether you follow SoFi, Amazon, Dutch Bros, or other high-growth names, we’ve got you covered. Explore our latest posts and stay tuned—new recaps and insights drop regularly.

Check out our dedicated Oscar Health page for all the latest posts and deep‑dives, from earnings breakdowns to fresh analyst takes—bookmark it and never miss a beat.

Written by Bryan Smith, creator of Straight From the Call.
I break down earnings calls so you don’t have to. Clear takeaways, no fluff — just the stuff investors care about.

This post is for informational and educational purposes only. It does not constitute financial, investment, or legal advice. Always do your own research or consult a licensed professional before making financial decisions. For the full policy, see our Not Investment Advice & Disclosure Statement.